All News

Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

d Jack Cush, MD

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
JIA,knee,synovitis

What Can JIA Patients Expect 18 Years In?

d MedPage Today

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

d Jack Cush, MD

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

d Jack Cush, MD

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
pregnancy,doctor,consult

COVID-19 in Pregnant Rheumatic Women

d Jack Cush, MD

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

Read Article
JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/6dRd6gnkjc

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM: A 14-year-old boy was admitted to this hospital because of fatigue, fever, joint pain, abdominal cramping, and diarrhea. Start w/ Sore, throat, then polyarthritis (knees, Shoul), fever 39.4C. Very high WBC, CRP & lipase. Whats the Dx?

Dr. John Cush RheumNow ( View Tweet)

Biomarker study of 21 systemic juvenile idiopathic arthritis (sJIA) shows you can differentiate between active & inactive disease. From 69 biomarkers, these were predictive: IL-6, MMP1, S100A12 (p < 0.0001), HMGB1; but IL-18 elevated in both groups! https://t.co/m2yXTITzwY

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center comparison of pts with MAS vs malignancy assoc. HLH (mHLH) - overall MAS had less hepatomegaly (0 v 25%), double platelet #s (50 v 29Kµ/L), but lower sIL-2R (6814 vs. 27,972.0) and less mortality (22 v 44%, p=0.18). https://t.co/NGIaPTU0yT

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast available for download. 2021 Rheumatology Year in Review https://t.co/0Lpo0IUBHp https://t.co/ysdwmQjeaS

Links:

Dr. John Cush RheumNow ( View Tweet)
There were significantly fewer FDA advisory committee meetings in 2021 (n=10), down dramatically from 35 in 2012, 29 in 2018. Nonetheless the FDA did approve 50 new drugs (NDA) in 2021. https://t.co/rSzHkIMEfg

Links:

Dr. John Cush RheumNow ( View Tweet)

Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/GxmgWIbgSo

Links:

Dr. John Cush RheumNow ( View Tweet)

Duloxetine added to usual analgesics failed to improve pain in 132 hip or knee OA pts by WOMAC pain scores: 1) Dulox + usual care vs 2) Usual care showed no diff in pain at 3 mos or 12 mos. https://t.co/9gR2PNVrPl

Links:

Dr. John Cush RheumNow ( View Tweet)

Good (long) open read review of Imaging in NPSLE (CNS lupus); mainly showing there is no SPECIFIC CNS imaging finding for NPSLE. Rather imaging (CT, MRI) done to r/o other pathology. PRES, PML, Vasculopathy, White matter lesions https://t.co/baUp6kjsKr

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of subcutaneous ianalumab in patients with primary Sjögren's syndrome met primary objective, showing dose-related decrease in disease activity (ESSDAI) at week 24: randomised, double-blind, placebo-controlled trial. https://t.co/NqdDWqpX2g https://t.co/PSxSRx28fM

Links:

The Lancet TheLancet ( View Tweet)
My patient measures morning stiffness in his joints by coffee units. Today, it’s 3 ☕️- an equivalent of 1 hour. #rheumatology

TheDaoIndex KDAO2011 ( View Tweet)

In Mouse Model of Lupus, when the gut microbiome of NZM2410 mice colonized w/ SFB, glomerulonephritis worsened & was assoc. w/ incr in TH17, MCP-1 and CXCL1, & more microbial abundance & biodiversity (dysbiosis) https://t.co/bLxrJZKTDZ

Links:

Dr. John Cush RheumNow ( View Tweet)

NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe

Links:

Dr. John Cush RheumNow ( View Tweet)

The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027. https://t.co/hQTDc0ajdN

Links:

Dr. John Cush RheumNow ( View Tweet)

×